Concepedia

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

Takayuki Yoshino, David C. Portnoy, Radka Obermannová, G. Bodoky, Jana Prausová, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, Pilar García‐Alfonso, Allen Lee Cohn, Eric Van Cutsem,

Annals of Oncology · 2018 · 65 citations · 23 references

DOIFull text

Open access

Concepts

References

23

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Eric Van Cutsem, Andrés Cervantes, René Adam et al. · Annals of Oncology · 2016 · 3.4K citations · Full text

, , +13

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Eric Van Cutsem, Josep Tabernero, Radek Lakomý et al. · Journal of Clinical Oncology · 2012 · 1.4K citations

, , +15

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson, Alan P. Venook, Lynette Cederquist et al. · Journal of the National Comprehensive Cancer Network · 2017 · 1.4K citations · Full text

, , +17

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology · 2015 · 955 citations

, , +12

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz et al. · JAMA · 2017 · 893 citations · Full text

, , +13